Prelude Capital Management’s Myriad Genetics MYGN Stock Holding History

Prelude Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-7,400	Closed	-$288K	–	2029
2014 Q2	$288K	Sell	7,400 -1,000	-12%	-$37.2K	0.04%	585
2014 Q1	$287K	Buy	8,400 +2,500	+42%	+$77.5K	0.04%	608
2013 Q4	$124K	Buy	5,900 +3,500	+146%	+$88.5K	0.02%	784
2013 Q3	$56K	Buy	+2,400	New	+$68.2K	0.01%	915

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's MYGN Position: Q4 2020 in Review

Prelude Capital Management sold out of Myriad Genetics (MYGN) in Q4 2020, closing a stake of 5,029 shares — an estimated $66K sold.

Prelude Capital Management first reported a position in MYGN in Q3 2013 and held it in 17 quarters. The position peaked at $809K in Q1 2017. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.

Prelude Capital Management reported no remaining Myriad Genetics position as of Q4 2020 after selling out during the quarter.
Prelude Capital Management sold 5,029 Myriad Genetics shares in Q4 2020, an estimated $66K.
Prelude Capital Management first reported a position in Myriad Genetics in Q3 2013 and held it in 17 quarters.
Prelude Capital Management's Myriad Genetics position peaked at $809K in Q1 2017.
187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.